Table 1.
BLI and neutralization potency of COVA1-18 IgG vs Fab in HEK293T hACE2 cells.
| IC50 | BLI | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMC (n ≥ 4) | Duke (n = 1) | Duke D614G (n = 1) | Nexelis (n = 1) | RBD loaded (n = 3) | Soluble S loaded (n = 3) | |||||||
| ng ml−1 | pM | ng ml−1 | KD (nM) | Ka (M−1s−1) | Kd (s−1) | KD (nM) | Ka (M−1s−1) | Kd (s−1) | ||||
| 1–18 | IgG | 1.7 | 11.3 | 9.0 | 7.0 | 9.0 | 7.0 | 1.7E+05 | 1.3E-03 | 5.0 | 3.7E+05 | 1.9E-03 |
| Fab | 199.0 | 3968.0 | N/A | N/A | N/A | 84.1 | 5.0E+04 | 4.1E-03 | N/A | N/A | N/A | |
AMC and Duke neutralization assays use lentiviral pseudotyped particles and HEK293T hACE2 cells. Nexelis neutralization assay uses VSVΔG pseudotyped particles and Vero E6 cells. BLI biolayer interferometry, RBD receptor binding domain.